Lexeo Therapeutics, Inc. 8-K

What Happened

• Lexeo Therapeutics, Inc. (NASDAQ: LXEO) filed a Form 8-K dated January 12, 2026 disclosing a press release announcing positive interim Phase 1/2 clinical data for its LX2020 program.
• The company also disclosed a corporate presentation to be used in connection with a webcast and furnished the press release and presentations as exhibits to the filing. The 8-K was signed by CEO R. Nolan Townsend.

Key Details

• Filing date: January 12, 2026 (Form 8-K).
• Exhibit 99.1: Press release announcing "Positive Interim Phase 1/2 Clinical Data of LX2020."
• Exhibits 99.2 and 99.3: Corporate presentations dated January 12, 2026 (one noted for use with the webcast).
• Item 7.01 (Regulation FD disclosure) and Item 8.01 (Other events) were reported; interactive XBRL cover page included as Exhibit 104.

Why It Matters

• A positive interim Phase 1/2 data announcement is a material clinical development for a biotech company—these disclosures provide investors with the company's latest clinical progress and program status.
• The press release and corporate presentation referenced in the 8-K are the primary sources for detailed trial results, next steps, and company commentary; investors should review those exhibits and any webcast for specifics (endpoints, patient numbers, safety and efficacy data).
• The Regulation FD disclosure and formal exhibit filing ensure the information was publicly released in compliance with disclosure rules, which is important for market transparency.